Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)

NEXT STORY
UPDATE — Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021
PREV STORY
Press release Biocartis Group NV: Results of the Extraordinary Shareholders’ Meeting held on 4 June 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Probiotic Ingredients Market To Reach USD 497.0 Million By 2027 | Growing Awareness and Demand for ‘Immunity Boosting’ Food-Products are Expected to Drive Market Growth, says Reports and Data

author_avatar
NASDAQ Market News

Trillium Therapeutics Reports Annual 2017 Financial and Operating Results

Presented evidence of clinical activity and good tolerability from both TTI-621 trials at ASHReceived ...

author_avatar
NASDAQ Market News

Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression

– Tipifarnib is a CXCL12 pathway inhibitor that may provide clinical benefit in subsets ...

author_avatar
NASDAQ Market News